In the past week, LLY stock has gone down by -1.10%, with a monthly decline of -3.47% and a quarterly surge of 4.17%. The volatility ratio for the week is 2.42%, and the volatility levels for the last 30 days are 2.88% for Lilly(Eli) & Co The simple moving average for the past 20 days is -6.44% for LLY’s stock, with a -4.76% simple moving average for the past 200 days.
Is It Worth Investing in Lilly(Eli) & Co (NYSE: LLY) Right Now?
Lilly(Eli) & Co (NYSE: LLY) has a higher price-to-earnings ratio of 70.94x compared to its average ratio. LLY has 36-month beta value of 0.50. Analysts have mixed views on the stock, with 16 analysts rating it as a “buy,” 7 as “overweight,” 5 as “hold,” and 0 as “sell.”
The public float for LLY is 850.00M, and currently, short sellers hold a 0.85% ratio of that float. The average trading volume of LLY on March 18, 2025 was 3.67M shares.
LLY) stock’s latest price update
The stock of Lilly(Eli) & Co (NYSE: LLY) has decreased by -1.18 when compared to last closing price of 824.76.Despite this, the company has seen a loss of -1.10% in its stock price over the last five trading days. seekingalpha.com reported 2025-03-17 that My DCF analysis suggests that Eli Lilly’s stock is 60% undervalued. Defensive healthcare stocks like Eli Lilly are favorable in the current uncertain macroenvironment, driven by tariff concerns and stable Fed policies. The company’s robust revenue growth, high R&D spending, and strategic positioning in the GLP-1 industry underscore its long-term growth prospects.
Analysts’ Opinion of LLY
Many brokerage firms have already submitted their reports for LLY stocks, with BofA Securities repeating the rating for LLY by listing it as a “Buy.” The predicted price for LLY in the upcoming period, according to BofA Securities is $997 based on the research report published on December 10, 2024 of the previous year 2024.
Wolfe Research, on the other hand, stated in their research note that they expect to see LLY reach a price target of $1000. The rating they have provided for LLY stocks is “Outperform” according to the report published on November 15th, 2024.
Bernstein gave a rating of “Outperform” to LLY, setting the target price at $1100 in the report published on October 17th of the previous year.
LLY Trading at -2.06% from the 50-Day Moving Average
After a stumble in the market that brought LLY to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -16.20% of loss for the given period.
Volatility was left at 2.88%, however, over the last 30 days, the volatility rate increased by 2.42%, as shares sank -4.55% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +5.15% upper at present.
During the last 5 trading sessions, LLY fell by -0.72%, which changed the moving average for the period of 200-days by +0.82% in comparison to the 20-day moving average, which settled at $871.22. In addition, Lilly(Eli) & Co saw 5.57% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at LLY starting from DONALD ZAKROWSKI, who proposed sale 2,000 shares at the price of $821.86 back on Mar 13 ’25. After this action, DONALD ZAKROWSKI now owns shares of Lilly(Eli) & Co, valued at $1,643,720 using the latest closing price.
Zakrowski Donald A, the SVP, Finance, & CAO of Lilly(Eli) & Co, sale 1,000 shares at $818.24 during a trade that took place back on Mar 13 ’25, which means that Zakrowski Donald A is holding 5,840 shares at $818,240 based on the most recent closing price.
Stock Fundamentals for LLY
Current profitability levels for the company are sitting at:
- 0.37 for the present operating margin
- 0.82 for the gross margin
The net margin for Lilly(Eli) & Co stands at 0.24. The total capital return value is set at 0.33. Equity return is now at value 84.84, with 14.84 for asset returns.
Based on Lilly(Eli) & Co (LLY), the company’s capital structure generated 0.7 points at debt to capital in total, while cash flow to debt ratio is standing at 0.26. The debt to equity ratio resting at 2.35. The interest coverage ratio of the stock is 23.91.
Currently, EBITDA for the company is 15.23 billion with net debt to EBITDA at 1.94. When we switch over and look at the enterprise to sales, we see a ratio of 17.84. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.15.
Conclusion
To put it simply, Lilly(Eli) & Co (LLY) has had a mixed performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
